We found that L-AZM treatment was associated with higher anti-inflammatory (IBA1+/CD206+) and lower pro-inflammatory (IBA1+I/L-1β+) macrophages after MI, particularly in peri-infarct regions. Here, AIF1 is linked to myocardial infarction.